Processa Pharmaceuticals (PCSA) AI Stock Analysis

• Market Cap: $8.03M
• Dividend Yield: N/A
• Average Volume (3M): 49.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: 72.88%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.81
• Shares Outstanding: 2,660,039
• 10 Day Avg. Volume: 70,293
• 30 Day Avg. Volume: 49,898
• PEG Ratio: <0.01
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.33
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.34K
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -6
• Revenue Forecast (FY): $10.01M

• Rating: 45 Neutral
• Price Target: $3.00 ▲(2400.00% Upside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

The score is held down primarily by weak financial performance (no revenue, continued losses, and ongoing cash burn despite low debt), implying meaningful funding risk. Technicals show short-term improvement but a still-weak longer-term trend with elevated momentum readings. Corporate events are mixed, while valuation metrics provide little support due to an uninformative P/E and no dividend yield.

Positive Factors

Focused oncology R&D strategy

Processa’s strategy targets improving safety and effectiveness of existing cancer therapies and uses regulatory/development approaches to accelerate clinical progress. That focus can shorten development timelines, lower scientific risk vs de novo drugs, and increase partner interest.

Negative Factors

No revenue; persistent net losses

The company has generated no revenue across multiple years while incurring recurring multi‑million dollar losses. That pre-commercial profile means the business is not self-sustaining, making long-term viability contingent on successful trials, partnerships, or financing.

Processa Pharmaceuticals Business Overview & Revenue Model

Company Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tabl...

Read more

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tabl...

How the Company Makes Money

null...

Processa Pharmaceuticals Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.20K	0.00	0.00	0.00	0.00
EBITDA	-13.99M	-12.05M	-11.46M	-19.47M	-10.78M
Net Income	-13.56M	-11.85M	-11.12M	-27.42M	-11.43M
Balance Sheet
Total Assets	7.81M	3.23M	5.79M	8.62M	26.46M
Cash, Cash Equivalents and Short-Term Investments	5.54M	1.19M	4.71M	6.50M	16.50M
Total Debt	0.00	73.51K	150.55K	229.45K	78.46K
Total Liabilities	2.24M	1.53M	797.48K	1.15M	978.40K
Stockholders Equity	5.58M	1.70M	4.99M	7.47M	25.49M
Cash Flow
Free Cash Flow	-11.39M	-11.25M	-8.07M	-9.61M	-8.72M
Operating Cash Flow	-11.39M	-11.25M	-8.06M	-9.61M	-8.72M
Investing Cash Flow	-850.00K	-3.24K	-2.78K	0.00	0.00
Financing Cash Flow	16.58M	7.73M	6.27M	-388.84K	9.80M

Processa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCSA, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 2.68, below the 50-day MA of 2.56, and below the 200-day MA of 5.04, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 56.70 is Neutral, neither overbought nor oversold. The STOCH value of 61.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCSA.

Processa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LPCN	48 Neutral	$14.60M	―	-59.29%	―	-44.31%	-34.17%
COCP	48 Neutral	$19.85M	-1.25	-94.94%	―	―	49.10%
SNGX	46 Neutral	$11.85M	-0.63	-248.01%	―	―	53.13%
PCSA	45 Neutral	$8.03M	-0.55	-257.81%	―	―	72.88%
CANF	41 Neutral	$7.25M	-0.33	―	―	―	―
PHGE	41 Neutral	$4.62M	-3.61	-154.50%	―	―	54.25%

Processa Pharmaceuticals Corporate Events